| | Title | Authors / Editors | Date |
|
unige:81146 |
Biodegradable nanoparticles for direct or two-step tumor immunotargeting |
Nobs, Leila; Buchegger, Franz; Gurny, Robert; Allémann, Eric |
2006 |
|
unige:20667 |
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants |
Wilbur, D Scott; Park, Steven I.; Chyan, Ming-Kuan; Wan, Feng; ... Press, Oliver W. |
2010 |
|
unige:13281 |
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles |
Cirstoiu, Adriana; Bossy-Nobs, L.; Buchegger, Franz; Gurny, Robert; Delie Salmon, Florence |
2007 |
|
unige:47276 |
Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody |
Alwayn, I P; Xu, Y; Basker, M; Wu, C; ... Cooper, D K |
2001 |
|
unige:20970 |
Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death |
Golay, Josee; Bologna, Luca; Andre, Pierre-Alain; Buchegger, Franz; ... Introna, Martino |
2010 |
|
unige:19810 |
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? |
Finckh, Axel; Ciurea, A.; Brulhart, L.; Moller, B.; ... Gabay, Cem |
2010 |
Antigens, cd20/immunology
add all
remove all
